Dolasetron: A new 5-hydroxytryptamine3 receptor antagonist

Cancer Practice

Volumn 5, Issue 5, 1997, Pages 324-328

  Hui, Yuk Fung ^a   Ignoffo, Robert J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; CARBOPLATIN; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOLASETRON MESILATE; DOXORUBICIN; DRUG METABOLITE; EPIRUBICIN; HYDRODOLASETRON; IFOSFAMIDE; SEROTONIN 3 ANTAGONIST; UNCLASSIFIED DRUG;

CANCER COMBINATION CHEMOTHERAPY; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG METABOLISM; HEADACHE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; POSTOPERATIVE COMPLICATION; RECEPTOR BLOCKING; REVIEW; SEROTONINERGIC SYSTEM; VOMITING;

ANTIEMETICS; HUMANS; INDOLES; NEOPLASMS; QUINOLIZINES; SEROTONIN ANTAGONISTS;

EID: 0031407275     PISSN: 10654704     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Bradley PB, Engel G, Feniuk W, et al. Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacology 1986; 25:563-576.
2. Harting PR. Molecular biology of 5-HT receptors. Trends Pharmacol Sci 1989; 10:64-69.
3. 3 (5-HT3) antagonists in the prevention of emesis caused by anticancer therapy. Biochem Pharmacol 1996; 52:685-692.
4. Tyers MB, Freeman AJ. Mechanisms of anti-emetic activity of 5-HT3 receptor antagonists. Oncology 1992; 49:262-268.
5. Miller RC, Galvan M, Gittos MW, et al. Pharmacological properties of dolasetron, a potent and selective antagonist at 5-HT3 receptors. Drug Dev Res 1993; 28:87-93.
6. Boxenbaum H, Gillespie T, Heck K, et al. Human dolasetron pharmacokinetics: I. Disposition following single-dose intravenous administration to normal male subjects. Biopharm Drug Dispos 1992; 13:693-701.
7. Boxenbaum H, Gillespie T, Heck K, et al. Human dolasetron pharmacokinetics: II. Absorption and disposition following single-dose oral administration to normal male subjects. Biopharm Drug Dispos 1993; 14: 131-141.
8. Dempsey E, Bourque S, Spenard J, et al. Pharmacokinetics of single intravenous and oral doses of dolasetron mesylate in healthy elderly volunteers. J Clin Pharmacol 1996; 36:903-910.
9. Lippert CL, Dimmett DC, Eller MG, et al. Pharmacokinetics of intravenous dolasetron in cancer patients receiving high-dose cisplatin-containing chemotherapy. Pharmacol Res 1995; 12(Suppl 9):S360. Abstract.
10. Rubenstein EB, Gralla RJ, Hainsworth JD, et al. Randomized, double blind, dose-response trial across four oral doses of dolasetron for the prevention of acute emesis after moderately emetogenic chemotherapy. Cancer 1997; 79:1216-1224.
11. Grote TH, Pindeda LF, Figlin RA, et al. Oral dolasetron mesylate in patients receiving moderately emetogenic platinum-containing chemotherapy. Cancer J Sci Am 1997; 3:45-51.
12. Rubenstein E, Fauser A, Grote T, et al. Determination of optimal dolasetron mesylate (DM) dose in prevention of acute nausea and vomiting (ANV) after moderately emetogenic chemotherapy (MECT) using pooled data from three pivotal trials. Proc Annu Meet Am Soc Clin Oncol 1996; 15:1722. Abstract.
13. Fauser AA, Duclos B, Chemaissani A, et al. Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy. Eur J Cancer 1996; 32A:1523-1529.
14. Kris MG, Pendergrass KB, Navari RM, et al. Prevention of acute emesis in cancer patients following high-dose cisplatin with the combination of oral dolasetron and dexamethasone. J Clin Oncol 1997; 15:2135-2138.
15. Otsuka A, Rizvi N, Modiano MR, et al. Dolasetron and dexamethasone prevent delayed emesis after high-dose cisplatin. Proc Annu Meet Am Soc Clin Oncol 1997; 16:273. Abstract.
16. Kirchner V, Aapro M. Safety and anti-emetic effect of MDL 73.147EF, a new 5HT3 antagonist in 41 patients requiring intravenous cytotoxic chemotherapy. Proc Annu Meet Am Soc Clin Oncol 1991; 10:1192. Abstract.
17. 3) receptor antagonist (MDL 73,147EF) in patients receiving high dose cisplatin chemotherapy. Proc Annu Meet Am Soc Clin Oncol 1992; 11:1377. Abstract.
18. Clark RA, Gralla RJ, Grunberg SM, et al. Effective single dose antiemetic treatment in patients receiving high cisplatin doses: establishment of the optimal IV dose of the 5-HT3 antagonist MDL 73,147EF. Proc Annu Meet Am Soc Clin Oncol 1992; 11:1325. Abstract.
19. Hesketh PJ, Gandara DR, Hesketh AM, et al. Dose-ranging evaluation of the antiemetic efficacy of intravenous dolasetron in patients receiving chemotherapy with doxorubicin or cyclophosphamide. Support Care Cancer 1996; 4:141-146.
20. Kris MG, Grunberg SM, Gralla RJ, et al. Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving cisplatin. J Clin Oncol 1994; 12:1045-1049.
21. Yeilding A, Bertoli L, Eisenberg P, et al. Antiemetic efficacy of two different single intravenous doses of dolasetron in patients receiving high-dose cisplatin-containing chemotherapy. Am J Clin Oncol 1996; 19:619-623.
22. Thant M, Pendergrass K, Harman G, et al. Double-blind, randomized study of the dose-response relationship across five single doses of dolasetron mesylate (DM) for prevention of acute nausea and vomiting (ANC) after cisplatin therapy (CCT). Proc Annu Meet Am Soc Clin Oncol 1996; 15:1727. Abstract.
23. Kasimis B, Tapazoglou E, Schulman P, et al. A double-blind, randomized study of two different regimens of intravenous (IV) dolasetron (DOL) in patients (PTS) receiving high dose cisplatin (CDDP) chemotherapy. Proc Annu Meet Am Soc Clin Oncol 1994; 13:1538. Abstract.
24. Harman GS, Omura GA, Ryan K, et al. A randomized, double-blind comparison of single-dose and divided multiple-dose dolasetron for cisplatin-induced emesis. Cancer Chemother Pharmacol 1996; 38:323-328.
25. Chevallier B, Cappelaere P, Splinter T, et al. A double-blind, multicenter comparison of intravenous dolasetron mesilate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin therapy. Support Cancer Care 1997; 5:22-30.
26. Fauser A, Bleiberg H, Chevallier B, et al. A double-blind, randomized comparative trial of IV dolasetron (D) vs IV metoclopramide (M) in prevention of emesis in moderately-emetogenic chemotherapy. Proc Annu Meet Am Soc Clin Oncol 1995; 14:1748. Abstract.
27. Audhuy B, Cappelaere P, Martin M, et al. A double-blind, randomized comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy. Eur J Cancer 1996; 32A:807-813.
28. Hesketh P, Navari R, Grote T, et al. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. J Clin Oncol 1996; 14:2242-2249.
29. Benedict CR, Arbogast R, Martin L, et al. Single-blind study of the effects of intravenous dolasetron mesylate versus ondansetron on electrocardiographic parameters in normal volunteers. J Cardiovasc Pharmacol 1996; 28:53-59.